Your shopping basket is empty.

Research & Trials

Fight Bladder Cancer supports evidence-based medicine for all those affected by bladder cancer.


If you have been affected by bladder cancer and would like to take part in research to improve services, please complete our sign-up form and we'll be in touch with opportunities to take part in various studies.

You can find a full list of open clinical bladder cancer trials in the UK below.

For non-UK trials, please go here.

Our research team

The Fight Bladder Cancer Research Division is currently working to progress the Fight Bladder Cancer Exemplar Study, develop further patient experience surveys and support Fight Bladder Cancer's involvement in ongoing clinical trials.

Research policy

Fight Bladder Cancer has not conducted or funded research involving animals, does not currently conduct or fund research involving animals, and has no plans to do so in the future. 

Fight Bladder Cancer supports research that will lead to better survival and quality of life for bladder cancer patients, with a focus on projects that have a direct impact on patient care

We campaign for a number of areas of research that are essential and long overdue, to give patients better survival and quality of life. 

Clinical Trials

A clinical trial is something that can be offered at any part in the bladder cancer journey, from initial suspected diagnosis, through investigations and different treatment, and in later follow-ups, or at the end of life.

There are a number of clinical trials in bladder cancer. These usually compare a new treatment which has the potential of working better or with less side effects, with what is used as the “gold-standard”.

Different trials are available in different hospitals. This is because of either the complexity of the trial or because of the type of treatment or test involved. For example, studies of surgery or radiotherapy may only be open at the particular hospital or cancer centres where the operation or the radiotherapy takes place. All studies have particular tick boxes to confirm whether this study is the correct one for you and your cancer. It may be that you and your type of bladder cancer do not match the eligibility criteria (or check list) for the study.

You should ask your doctor if you are suitable for a clinical trial. It is always helpful to take information with you for any trials that your doctor may not be familiar with. If the study is open elsewhere in the UK and it looks as though you may be eligible for this (and are prepared to travel), you could ask your doctor to refer you. 

Current Open Bladder Cancer Trials


Suspected Bladder Cancer


This trial will need a urine sample from participants who are under investigation for possible bladder cancer and are due to undergo a standard-of-care investigative cystoscopy and biopsy. This study tests whether the UroX biomarker can be detected in urine samples and therefore be a way of diagnosing patients. Both healthy volunteers and bladder cancer participants are needed. 

East and North Hertfordshire NHS Trust ID: NCT03973307


Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.

The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device. The primary objective of the study is to assess whether significant changes in DNA mutation and methylation associated with Non-colorectal cancers of the Aerodigestive Tract (NCRCADT) can be detected in rectal mucus as shed cells and cell-free DNA (cfDNA) pass through the gut and theoretically can be collected from rectal mucus. Secondary objectives will assess the participant acceptability of the OriCol™ Sampling Device for Upper GI and Lung Pathology as well as contributing to a genomic library collating information about rectal mucus

Royal Devon & Exeter NHS Foundation Trust, Exeter ID:  NCT05102110


Urinary tract squamous cell carcinoma (UTSCC)


This trial is for people with urinary tract squamous cell carcinoma (UTSCC). People participating in this trial will receive an immunotherapy called atezolizumab. This study is investigating whether atezolizumab is tolerable, safe and will help prolong the life of people with urinary tract squamous cell carcinoma.

Locations: University Hospital Southampton, University College London Hospital, James Cook Hospital Middlesborough, Western General Hospital Edinburgh, Beatson West of Scotland Cancer Centre Glasgow, Royal Preston Hospital, Nottingham, Velindre (Cardiff), The Christie Hospital Manchester, Clatterbridge Hospital Liverpool, Royal Marsden Hospital ID: NCT05038657


Non-Muscle-Invasive Bladder Cancer (NMIBC)


This trial examines the effectiveness and safety of combining pembrolizumab, a cancer immunotherapy, with BCG therapy in treating high-risk non-muscle invasive bladder cancer. It targets patients who either have persistent or recurrent cancer after BCG treatment or are new to BCG therapy. The study aims to determine if the combined treatment is more effective than BCG alone in achieving a complete response and extending the time without cancer symptoms.

Locations: Raigmore Hospital, Inverness, Highland, IV2 3UJ; St Bartholomew's Hospital, London, London, EC1A 7BE; St Georges University Hospitals NHS Foundation Trust, London, London, SW17 0QT ID: NCT03711032



The DURANCE trial is a study looking at the combination of durvalumab, an immune checkpoint inhibitor, with a novel cancer vaccine (S-488210/S-488211) in people with non-muscle invasive bladder cancer who are unresponsive to or intolerant of BCG therapy. This research aims to determine the safety and effectiveness of this combination treatment, administered over a period of up to 24 weeks. People receive durvalumab intravenously every four weeks and the vaccine through injections, beginning a day after the first durvalumab dose. The study includes an initial evaluation at 12 weeks with a cystoscopy to decide if people should continue based on their response to the treatment.

Locations: Guy's and St Thomas' NHS Foundation Trust, London; The Royal Marsden NHS Foundation Trust, London; University College London Hospital NHS Foundation Trust, London; University Hospital Southampton NHS Foundation Trust, Southampton ID: NCT04106115



This study is for people with high-risk Non-Muscle Invasive Bladder Cancer. TAR-200 is inserted into the bladder - it is an investigational product that is comprised of a drug (Cetrelimab) and a medical device. This study consists of 3 periods: screening phase (up to 42 days); treatment phase (up to 2 years); follow-up phase (up to 5 years). The total duration of study is up to 6 years and 7 months.

NHS Greater Glasgow and Clyde Identifier: NCT04640623


RESECT: Improving Quality in TURBT Surgery.

The most important step in the diagnosis and treatment of Non-Muscle Invasive Bladder Cancer is the first surgical procedure called the transurethral resection of bladder tumour (TURBT). There is evidence that the quality of the TURBT operation, and the use of a single administration of bladder chemotherapy following the operation, can reduce cancer recurrence rates and progression to more invasive cancer. There is anecdotal evidence that the quality of TURBT surgery and the usage of intravesical chemotherapy varies widely between hospitals and thus may result in worse outcomes for some patients.

The primary objective of the study is to determine if audit and feedback can improve the quality of TURBT surgery and if this reduces the recurrence of Non-Muscle Invasive Bladder Cancer

BURST, London ID: NCT05154084



This clinical trial is testing a new drug called enfortumab vedotin for people with non-muscle invasive bladder cancer. The drug is administered directly into the bladder through a catheter to see if it can effectively treat the cancer. Researchers will also monitor the side effects to ensure the drug is safe for patients. The goal is to find the most effective dose that causes the fewest side effects in part one of the study, and then use that dose in part two to further evaluate its effectiveness.

Location: London, EC1A 7BE ID: NCT05014139


Muscle-invasive, advanced or metastatic bladder cancer


This study is for people with locally advanced or metastatic urothelial cancer. It is a randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy before maintenance avelumab immunotherapy.

Queen Mary University of London, Western General Hospital Edinburgh 2021-001975-17



This study is for people with cancer of the urinary system that has spread to other places in the body (advanced urothelial cancer). Patients will be receiving a drug called atezolizumab. Upon entering the study, patients will continue to receive atezolizumab and may also receive five doses of radiotherapy. This study investigates whether radiotherapy can improve response to atezolizumab for people treated for advanced urothelial cancer.

London, Manchester, Sutton, Truro

International Trial Number: ISRCTN12606219



This study is for people with muscle-invasive or advanced bladder cancer. It aims to determine the safety and effectiveness of immunotherapy with radiotherapy. It is a phase 1 clinical trial and will start with pembrolizumab before beginning a radiotherapy course.

Royal Marsden NHS Foundation Trust ID: NCT02560636


A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

The primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for JNJ-63723283 in Part 1, to assess the anti-tumour activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/oesophagal cancer, and high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) in Part 2, to determine one or more additional RP2Ds in Parts 3 and 4 and to evaluate JNJ-63723283 subcutaneous (SC) administration pharmacokinetics (PK) compared to JNJ-63723238 intravenous (IV) administration (Part 5).

Beatson West Of Scotland Cancer Centre,  Glasgow; Sarah Cannon Research Institute, London,  The Christie NHS Foundation Trust, Manchester,  Sir Bobby Robson Unit, Northern Centre for Cancer Care, Newcastle upon Tyne ID: NCT02908906


Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

This study is for people with muscle-invasive bladder cancer. This study looks at the use of the drug nivolumab with chemotherapy.

Chelmsford,  York,  Glasgow,  Lancaster,  London,  Oxford ID: NCT03661320



This study looks at the drug RP1 alone and then RP1 with nivolumab. This trial needs participants with advanced and/or refractory solid tumours. This trial will determine the drug's maximum tolerated and recommended dose. It is for a range of cancers and includes bladder cancer. 

University of Leeds- Teaching Hospital,  Oxford University Hospitals NHS Trust,  Beatson West of Scotland Cancer Center Glasgow,  The Clatterbridge Cancer Centre NHS Foundation Trust Bebington,  Royal Marsden Hospital London,  Southampton General Hospital ID: NCT03767348


Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

This study is for people with advanced or metastatic bladder cancer previously treated with chemotherapy. Patients will receive a drug called atezolizumab. This study looks at how well this drug works in people with bladder cancer.

Barnet Hospital,  Royal United Hospital Bath,  Clatterbridge Cancer Centre Bebington,  Heartlands Hospital Birmingham,  Addenbrookes Hospital Cambridge,  Royal Surrey County Hospital Guildford,  Northwick Park Hospital Harrow,  Hull Royal Infirmary,  Airedale General Hospital Keighley,  Royal Marsden Hospital Kingston upon Thames,  St Bartholomew's Hospital London,  Royal Free Hospital London,  Guys and St Thomas Hospital London,  Queen Elizabeth Hospital London,  St George's Hospital London,  Royal Marsden Hospital, Fulham London,  Hammersmith Hospital London,  Charing Cross Hospital London,  Maidstone Hospital,  The Christie Manchester,  James Cook Hospital Middlesbrough,  Freeman Hospital Newcastle upon Tyne,  Nottingham City Hospital,  Churchill Hospital Oxford,  Weston Park Hospital Sheffield,  Royal Stoke University Hospital,  Royal Marsden Hospital Sutton,  Torbay Hospital,  Pinderfields General Hospital Wakefield,  Great Western Hospitals Wiltshire,  New Cross Hospital Wolverhampton,  York Hospital ID: NCT03782207 


A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

Exelixis Clinical London,  Sutton,  Preston ID: NCT03845166



This study is for advanced or metastatic bladder cancer patients who have progressed during or following chemotherapy. Patients will receive a drug called atezolizumab and perhaps one of the following drugs: enfortumab vedotin, niraparib, Hu5F9-G4, tiragolumab, sacituzumab govitecan, cisplatin, gemcitabine or tocilizumab.

Barts and The London,  Churchill Hospital Oxford,  Royal Marsden NHS Foundation Trust Sutton ID: NCT03869190



This clinical trial is examining the effects of perioperative pembrolizumab, alone or with enfortumab vedotin, in people who are ineligible for cisplatin chemotherapy or who opt out of its use, and who have muscle-invasive bladder cancer. The study aims to see if these drug combinations along with surgery (radical cystectomy and pelvic lymph node dissection) improve survival compared to surgery alone.  The trial is crucial for understanding whether these advanced drug treatments can offer better outcomes than traditional surgery methods.

Locations: Barts Health NHS Trust - St Bartholomew's Hospital, London, EC1A 7BE; The Royal Marsden Foundation Trust, London, SW3 6JJ; Imperial College Healthcare NHS Trust, London, W6 8RF; Western General Hospital, Edinburgh, Midlothian, EH4 2XU; The James Cook University Hospital, Middlesbrough, England, TS4 3BW; Clatterbridge Oncology Centre, Wirral, CH63 4JY ID: NCT03924895


A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With Ezabenlimab With or Without BI 754111

This study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumors). The second part is open to people with specific types of soft tissue sarcoma, advanced lung cancer, and cancer in the stomach, bladder or bile ducts.

The Royal Marsden Hospital, London ID:  NCT03964233



In this study, researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumour that currently available drugs cannot cure. Researchers want to find the highest dose of BAY2416964 that participants could take without having too many side effects, how the drug is tolerated, and how the body absorbs, distributes and gets rid of the study drug.

Royal Marsden NHS Trust Surrey,  Beatson West of Scotland Cancer Centre Glasgow,  Christie Hospital Manchester ID: NCT04069026



This registry helps implement the MRI-guided Linear Accelerator radiation therapy system to improve patients' survival, local and regional tumour control and quality of life.

London, Manchester ID: NCT04075305


A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

Leicester Royal Infirmary ID:  NCT04104776


Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors. The main goals of this study are to:
1. Find the recommended dose of BT5528 that can be given safely to participants alone and in combination with nivolumab
2. Learn more about the side effects of BT5528
3. Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer.
4. Learn more about BT5528 therapy alone and in combination with nivolumab

Cambridge University Hospitals NHS Foundation Trust,  St James's University Hospital, Leeds,  Sarah Cannon Research Institute UK, London,  The Christie NHS Foundation Trust, Manchester,  Sir Bobby Robson Cancer Trials Research Centre,  Newcastle Upon Tyne ID:  NCT04180371



This study is for people who have muscle-invasive bladder cancer. Patients will receive chemoradiotherapy and might also receive a drug called pembrolizumab. This study looks at how well pembrolizumab works with chemoradiotherapy in people with bladder cancer.

South Devon Healthcare Foundation Trust ID: NCT04241185


A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT to determine whether it is safe for patients with solid tumours and lymphomas. It will study SEA-TGT to find out what its side effects are. It will also study whether SEA-TGT works to treat solid tumours and lymphomas.

The Royal Marsden Hospital Surrey ID: NCT04254107


Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety of INCB099318 in people with solid tumours. People in this study will be given INCB099318, an immunotherapy drug that is taken as a tablet. 

Western General Hospital Edinburgh,  St James University Hospital Leeds,  Guys and St Thomas NHS Foundation Trust London,  The Royal Marsden Hospital NHS Trust London,  Imperial College Healthcare NHS Trust Hammersmith Hospital London,  Freeman Hospital Newcastle Upon Tyne ID:  NCT04272034


A Study of SGN-B6A in Advanced Solid Tumors

This trial will look at a drug called SGN-B6A to determine whether it is safe for people with solid tumours. It will study SGN-B6A to find out what its side effects are. It will also study whether SGN-B6A works to treat solid tumours.

The Royal Marsden Hospital Surrey ID: NCT04389632


REFOCUS (RLY-4008-101)

This study is for people whose cancer cannot be removed with surgery or has spread to distant body parts. People must be positive for the FGFR2 biomarker to be eligible. Participants in the study will receive an investigational drug called RLY-4008. This Phase 1/2 clinical study is looking at the safety and clinical benefit (tumour shrinkage) of RLY-4008.

Sarah Cannon Research Institute London, University College London Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust Manchester ID: NCT04526106


Study DRUG BT8009 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies

Evaluating a drug called BT8009 alone and in combination with pembrolizumab in participants with advanced solid tumours associated with Nectin-4 expression or in participants with advanced solid tumour having kidney problems. The main goals of this study are to:
1. Find the recommended dose of BT8009 that can be given safely to participants alone and in combination with pembrolizumab
2. Learn more about the side effects and effectiveness of BT8009 alone and in combination with pembrolizumab
3. Learn more about BT8009 alone and in combination with pembrolizumab
4. Learn more about BT8009 alone in patients with renal insufficiency

Sarah Cannon Research Institute UK, London,  The Christie NHS Foundation Trust, Manchester ID:  NCT04561362


Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

This trial studies how well tucatinib works for solid tumours that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumours studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab

The Royal Marsden Hospital, London,  Sarah Cannon Research Institute UK, London,  The Royal Marsden Hospital (Surrey), Sutton,   Guy's Hospital, London, ID:  NCT04579380


INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

This is a clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumours including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC)

Cambridge University Hospitals NHS Foundation Trust,  University of Glasgow, Glasgow,  Guys and St Thomas NHS Foundation Trust, London,  Imperial College Healthcare NHS Trust - Hammersmith Hospital, London,  The Christie NHS Foundation Trust Manchester,  Freeman Hospital Newcastle Upon Tyne Foundation NHS Trust ID:  NCT04580485


Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer (ABACUS-2)

See if the drug atezolizumab can reduce the size of tumours in patients with types of urothelial cancer before surgery. Atezolizumab is designed to stop a protein called PD-L1 (programmed death-ligand 1) being expressed on the cancer, allowing the immune system to recognise the tumour cells as foreign bodies and attack them. Atezolizumab has been shown to have activity in urothelial cancer which has spread.

Barts and London Hospital NHS Trust, London, ID:  NCT04624399


AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Research Site, Cambridge,  Manchester,  Oxford,  Sutton Identifier:  NCT04644068



This study is for people with high-risk muscle-invasive bladder cancer who have had a cystectomy. Patients will be followed up closely after their cystectomy and may receive the immunotherapy atezolizumab. This study is looking to see if atezolizumab can improve disease-free survival.

Belfast City Hospital,  Addenbrookes Hospital,  Western General Hospital Edinburgh,  St James Hospital,  Barts Hospital, University College London NHS Foundation Trust,  Derriford Hospital,  Royal Preston Hospital,  Weston Park Hospital,  Southampton University Hospitals NHS Trust,  Royal Marsden Hospital (Sutton). ID: NCT04660344


Magrolimab in Participants With Solid Tumors

Evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab + docetaxel combination therapy in solid tumors (Safety Run-in Cohort 1, Phase 2 Cohorts 1a, 1b, and 1c) and to evaluate the efficacy of magrolimab + docetaxel combination therapy in solid tumors as determined by investigator-assessed objective response rate (ORR) (Phase 2 Cohorts 1a, 1b, and 1c)

Barts Health NHS Trust, London,  Guy's and St Thomas' NHS Foundation Trust, London ID:  NCT04827576


A Study of Disitamab Vedotin Alone and With Pembrolizumab in Urothelial Cancer That Expresses HER2

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug

Barts Health NHS Trust Saint Bartholomews Hospital, London ID:  NCT04879329


TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.

Barts Health NHS Trust, London ID:  NCT04919512



A study to determine the efficacy and safety of durvalumab in combination with tremelimumab and enfortumab vedotin or durvalumab in combination with enfortumab vedotin in people ineligible for chemotherapy undergoing radical cystectomy for muscle-invasive bladder cancer

Research Sites: Blackburn BB2 3HH, Bristol BS2 8ED, Gillingham ME7 5NY, Glasgow G12 0XH, London EC1A 7BE, London NW1 2PG, Sheffield S10 2RX ID: NCT04960709


A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range of solid tumour types to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). In Phase 1b, the selected RP2D dose will be assessed in one to three tumour types.

The Beatson West of Scotland Cancer Centre Glasgow,  St James's University Hospital Leeds,  The Royal Marsden, NHS Foundation Trust, London,  The Christie NHS Foundation Trust, Manchester,  The Freeman Hospital, Newcastle-upon-Tyne,  Weston Park Cancer Centre Sheffield Identifier: NCT04969835



The investigators would like to test stool samples of patients with womb, cervix or bladder cancer having pelvic radiotherapy to see if there are differences in the type of gut bacteria between those who get severe bowel symptoms compared to those with mild bowel symptoms. They also want to see whether these differences in gut bacteria can tell who will develop severe bowel symptoms during or after radiotherapy and determine the effect of diet.

Manchester Identifier: NCT04995809


BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab

Researchers are looking for a better way to treat advanced solid cancers including head and neck cancer, lung cancer and bladder cancer. In some people with cancer a protein called Aryl Hydrocarbon Receptor (AhR) can prevent immune cells from fighting tumor cells. The study drug, BAY 2416964, is a small molecule which blocks the AhR allowing the body to use its immune response against the cancer cells. Researchers think that BAY 2416964 given together with a cancer treatment called pembrolizumab may help shrink tumors in people with cancer

Clatterbridge Centre for Oncology, Bebington, Merseyside,  Belfast City Hospital, Belfast,  Freeman Hospital, Newcastle Upon Tyne Identifier: NCT04999202


HMBD-001 in Advanced HER3 Positive Solid Tumours

This study evaluates HMBD-001 for treating people with bladder cancer who test positive for the HER3 biomarker. The main aims are to find out the maximum dose of HMBD-001 that can be given safely to patients alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how these can be treated.

Royal Marsden NHS Foundation Trust, London,  Churchill Hospital, Oxford Identifier: NCT05057013


Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Royal Marsden Hospital (Chelsea), London,  The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle,  Royal Cornwall Hospitals NHS Trust Identifier NCT05059522


IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Urothelial Bladder Cancer (mUBC)

Guys and St Thomas Hospital, London Identifier NCT05077709


A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies

Royal Marsden Hospital NHS Foundation Trust, Sutton,  University College London Hospitals NHS Foundation,  Addenbrookes Cambridge University Hospital, Cambridge,  Beatson West of Scotland Cancer Centre, Glasgow,  Sarah Cannon Research Institute, London,  The Christie NHS Foundation Trust, Manchester,  Churchill Hospital, Oxford ID: NCT05107674


Ex VIvo DEtermiNed Cancer Therapy (EVIDENT)

EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield ID:  NCT05231655


Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).

Through our study, we aim to understand the most important factors for patients when they decide on the type of treatment they receive for MIBC. Our study consists of a discrete choice experiment (DCE): a type of questionnaire used to elicit preferences in the absence of data. DCEs are frequently used in oncological research to elicit preferences from participants without directly asking them to state their preferred options. Participants undertaking our DCE questionnaire will presented with a series of alternative hypothetical scenarios containing several variables or "attributes" (5), each of which may have a number of variations or "levels".

Guy's and St Thomas' NHS Foundation Trust, London ID: NCT05236218



A multi-centre non-interventional study to describe the early clinical experience of avelumab used as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy

University Hospitals Bristol, Bristol,  Beatson West of Scotland Cancer Centre, Glasgow,  Royal Surrey County Hospital, Guildford,  Guy's and St Thomas' Hospital, London,  The Christie NHS Foundation Trust, Manchester,  Churchill Hospital, Oxford,  Royal Preston Hospital, Preston,  Lister Hospital, Stevenage,  Clatterbridge Hospital, Wirral, ID: NCT05366725


Human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours

Research Sites: Cambridge,  Glasgow,  London,  Newcastle Upon Tyne ID: NCT05397171


Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer

The gut bacteria can potentially influence responses to treatments in cancer by helping to change the responses to radiotherapy and chemotherapy. The interactions between these bacteria and the rest of our cells are only now becoming understood and there is little research on the interactions between these bacteria and cancer radiotherapy treatments in pelvic cancer

Aberdeen Royal Infirmary, Aberdeen ID: NCT05605353


Find out more about how we can support trials and research.

Please contact us direct for any further information requirements on 01844 351621 or email us direct at 

Research downloads

To see a full set of our downloads please see our Downloads page.

Get in touch

We’ve tried to make the information on this site as accurate as possible. Whilst we have support from medical professionals to review the general medical content of this site, please remember that only your medical team can give you specific advice about your symptoms or illness. Fight Bladder Cancer is a registered Charitable Incorporated Organisation in Scotland (SC051881), England and Wales (1198773), and was initially established as an unincorporated charity in England and Wales (1157763). It also operates in Northern Ireland.